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Oxidative stress, disrupted copper homeostasis, and neuroinﬂammation due to overproduction of proinﬂammatory cytokines are
considered leading causative factors in development of age-associated neurodegenerative conditions. Recently, a new mechanism
of aging—detrimental epigenetic modiﬁcations—has emerged. Thus, compounds that possess antioxidant, anti-inﬂammatory
activity as well as compounds capable of restoring copper balance and proper gene functioning may be able to prevent age-
associated cognitive decline and ward oﬀ many common neurodegenerative conditions. The aim of this paper is to bring attention
toacompoundwithalonghistoryofsafeuseinwoundhealingandantiagingskincare.ThehumantripeptideGHKwasdiscovered
in 1973 as an activity in human albumin that caused old human liver tissue to synthesize proteins like younger tissue. It has high
aﬃnityforcopperionsandeasilyformsacoppercomplexorGHK-Cu.Inaddition,GHKpossessesaplethoraofotherregenerative
and protective actions including antioxidant, anti-inﬂammatory, and wound healing properties. Recent studies revealed its
ability to up- and downregulate a large number of human genes including those that are critical for neuronal development and
maintenance. We propose GHK tripeptide as a possible therapeutic agent against age-associated neurodegeneration and cognitive
decline.
1.Introduction
Today the most widespread neurological problems are
considered neurodegenerative diseases of aging such as
Alzheimer’s and Parkinson’s that rob people from their
golden years causing early debilitation and dependency
on special care. Despite all advances in neuroscience in
recent decades, age-associated cognitive decline resulting
from neurodegenerative processes in the brain remains a
challenge for researchers and clinicians due to the highly
complex nature of its pathogenesis.
Currently, the key processes leading to neurodegenera-
tion are thought to be oxidative stress, disruption of transi-
tional metal homeostasis, and neuroinﬂammation [1, 2].
There is also growing evidence that neurodegenerative
diseases such as Alzheimer’s and Parkinson’s may be caused
by detrimental environmental and dietary factors that alter
gene expression by means of DNA methylation and histone
modiﬁcation [3].
Since the importance of oxidative stress in the
development of age-related neurodegeneration is well
established, a number of antioxidant compounds are
considered promising in prevention of neurodegenerative
disorders, including vitamin E, melatonin, green tea
polyphenols, resveratrol, and others [4]. However, so far the
clinical studies produce mixed results with many promising
approaches such as vitamin E therapy failing to slow down
the progression of age-related neurodegenerative conditions
[5]. There are also studies investigating an eﬀect of metal
chelators and dietary approaches aimed at reducing intake
of iron and copper [6]. Finally, researchers are investigating
diverse compounds capable of favorably altering gene
expression (epigenetic modiﬁers), reversing eﬀects of
environmental perturbagens [7].2 Oxidative Medicine and Cellular Longevity
The human copper-binding tripeptide glycyl-L-histidyl-
L-lysine (GHK) is a compound with a long history of safe
use in wound healing and antiaging skin care. Since its
discovery in 1973, almost four decades of extensive research
have established its diverse beneﬁcial actions in many organs
and tissues including nervous tissue, skin, intestine, bone,
andbloodvessels.ThemoleculehasahighaﬃnityforCu(II)
and forms the chelate GHK-Cu. The GHK copper complex
(or GHK-Cu) has been proven to exhibit antioxidant, anti-
inﬂammatory, regenerative, and wound healing actions [8].
Recent studies demonstrated that the GHK tripeptide up-
and downregulates a large number of human genes, which
may contribute to the pleiotropic health promoting eﬀects
of its copper complex [9]. We propose that the GHK-
Cu complex may act therapeutically against age-associated
neurodegeneration and cognitive decline.
2. Copper Binding Propertiesof the Human
TripeptideGHK
Human peptide GHK was isolated in 1973 as an activity
in human plasma that caused old human liver tissue to
synthesize proteins like younger tissue [10]. In human
plasma GHK is present at about 200 micrograms/liter in
men of age 20–25 but declines to 80 micrograms/liter by
age 60–80. Subsequent studies established this activity as a
tripeptide with an amino acid sequence glycyl-L-histidyl-L-
lysine with a strong aﬃnity for copper that readily formed
the complex GHK-Cu. Since GHK-Cu promotes cell growth,
it was proposed that the GHK acts by delivering copper
required for the cellular functions into the cell in a form that
is nontoxic and can be utilized by the cell [11].
The molecular structure of the GHK copper complex
(GHK-Cu) has been extensively studied using X-ray crystal-
lography, EPR spectroscopy, X-ray absorption spectroscopy,
and NMR spectroscopy as well as other methods such
as titration. In the GHK-Cu complex, the Cu (II) ion is
coordinated by the nitrogen from the imidazole side chain
of the histidine, another nitrogen from the alpha-amino
group of glycine, and the deprotonated amide nitrogen of
the glycine-histidine peptide bond (Figure 1). Since such a
structure could not explain a high stability constant of the
GHK-Cu complex (log10 = 16.44 versus 8.68 of the GH
copper complex, which is similar to the GHK-Cu structure),
it was proposed that another amino group participates
in the complex formation. According to the recent study
by Hureau et al., the Cu (II) is also coordinated by the
oxygen from the carboxyl group of the lysine from the
neighboring complex. Another carboxyl group of lysine
from a neighboring complex provides the apical oxygen,
resulting in the square-planar pyramid conﬁguration. Many
researchers proposed that, at the physiological pH, GHK-
Cu complexes can form binary and ternary structures which
may involve amino acid histidine and/or the copper binding
region of the albumin molecule. Lau and Sarkar found
also that GHK can easily obtain copper 2+ bound to other
molecules such as the high aﬃnity copper transport site
on plasma albumin (albumin binding constant log10 = 16.2
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Figure 1: Molecular structure of the tripeptide GHK-Cu. In
solution lysine carboxyl groups of neighboring complexes may
participate in a complex formation.
versus GHK binding constant 16 log10 = 16.44). It has been
established that copper (II) redox activity is silenced when
copper ions are complexed with the GHK tripeptide, which
allows the delivery of nontoxic copper into the cell [12–14].
3.The Copper Paradox
The brain is exceptionally rich in copper, which plays an
important role in its physiology and pathology. Copper
deﬁciency caused by bariatric surgery or gastrointestinal
bleeding led to myelopathy (human swayback), paralysis,
blindness, and behavioral and cognitive changes [15–17].
Mice born and maintained on a copper-deﬁcient diet had
80% reduction in brain copper level at 6–8 weeks and had
neuronal and glial changes typical for neurodegenerative
disorders [18].
Despite unquestionable essentiality of copper, unreg-
ulated copper ions may increase oxidative damage. It is
known that amyloid precursor protein (APP) implicated in
development of Alzheimer’s disease (AD) can convert Cu
(II) into Cu (I) potentially increasing oxidative damage [19].
However, it remains unclear whether copper accumulation
in senile plaques of AD patients is a cause or a consequence
of pathological processes observed in AD. According to
Exley followed by Bolognin et al., only aluminum, but not
copper or iron, is capable of triggering amyloid precipitation
and APP and tau181 protein overproduction [20, 21].
The study by Kawahara et al. showed that copper and
carnosine attenuate neurotoxicity of another compound
involved in neurodegeneration—prion protein [22]. Bishop
and Robinson observed that amyloid beta protein may be
neuroprotective when combined with copper. According to
these authors, amyloid beta injected simultaneously with
copper was not toxic, while iron and zinc complexed with
amyloid beta were more toxic than amyloid beta alone [23].
Since copper accumulates in senile plaques of AD
patients,someauthorsproposeddietaryrestrictionofcopper
or intake of copper chelators as a preventive therapy for
the elderly. However, several studies demonstrated that ADOxidative Medicine and Cellular Longevity 3
patients have reduced, not elevated, brain and cerebrospinal
ﬂuid copper level [24, 25]. Currently, many authors suggest
mild copper deﬁciency as a causative factor in AD and
possibly other neurodegenerative disorders [26, 27]. In
a placebo-controlled, double-blinded, randomized clinical
trial, oral copper supplementation (8mg/day) in 68 AD
patients had a beneﬁcial eﬀect on relevant AD biochemical
markers. The authors concluded that long-term intake of
c o p p e rc a nb ee x c l u d e da sac a u s a t i v ef a c t o ri nA Da n d
may in fact be protective [28]. In addition, several studies
revealed molecular mechanisms underlying beneﬁcial eﬀects
of copper in AD, such as an inhibition of beta-amyloid
peptide production [29].
Due to high importance of copper in the brain
metabolism and a possible role of copper deﬁciency in the
development of Alzheimer’s and other neurodegenerative
disorders,limitingofthedietarycopperintakeinelderlymay
actually increase their chance of developing neurodegener-
ative disorders. Another option is to use compounds that
can form nontoxic complexes with Cu (II), preventing its
accumulation in senile plaques and increasing its bioavail-
ability. According to Narahara et al., β-citryl-L-glutamate—
a compound that is abundant in the developing brain—
has SOD-like activity when complexed with copper and
may be neuroprotective [30]. R´ ozga and Bal propose that
human serum albumin (HSA) may be neuroprotective due
to its ability to bind both copper and amyloid beta protein
[31]. Perrone at al. reported copper transfer from amyloid
beta to a copper binding domain of HSA that is similar
to the tripeptide GHK’s structure with the same copper-
binding histidine residue (DAHK) [32]. Thus GHK peptide,
a natural copper-binding and copper-regulating molecule
with well-established regenerative and protective actions
in diﬀerent organs and tissues, should be considered a
promising therapeutic agent in preventing and correcting
copper imbalance in neurodegenerative disorders.
4. Antioxidant and Anti-Inﬂammatory
Properties of GHK-Cu
The brain’s high metabolic activity results in elevated oxygen
consumption and constant production of reactive oxygen
species (ROS) in mitochondria. At the same time, the
brain tissue is rich in unsaturated fatty acids and transition
metal ions yet has relatively fewer antioxidants comparing
to other organs creating favorable conditions for oxidative
damage. Since the blood-brain barrier prevents many dietary
antioxidants from entering the brain, it largely relies on
endogenous antioxidants such as Cu- and Zn-dependent
superoxide dismutase (Cu, Zn SOD1). This enzyme requires
metal ions copper and zinc in order to be active. Hence,
copper deﬁciency can lead to reduced SOD activity and
increased oxidative brain damage [33]. When pregnant rats
were kept on a copper-deﬁcient diet, the embryos displayed
low SOD activity, increased super oxide anion radical level,
and higher incidence of DNA damage and malformations
[34]. Amyloid precursor protein (APP) that is implicated in
Alzheimer’s disease (AD) development has copper binding
activity and can trap copper, rendering brain tissue copper
deﬁcient. Transgenic mice overexpressing APP had reduced
SOD1 activity in the brain. SOD1 activity was restored by
copper supplementation [35]. It has been shown that GHK-
Cu increases the level of antioxidant enzymes and SOD
activity, supposedly by supplying copper necessary for its
function [36].
GHK-Cu also reduces oxidative damage by modulating
iron levels. The presence of iron complexes in damaged
tissues is detrimental to wound healing, due to the increased
lipid peroxidation in the presence of iron ions, as well as
microbial infection mediated by iron. Pickart demonstrated
that GHK-Cu inhibited lipid peroxidation if the iron source
was ferritin. It was proposed that GHK-Cu binds to the
c h a n n e l so ff e r r i t i ni n v o l v e di ni r o nr e l e a s ea n dp h y s i c a l l y
prevents the release of Fe (II). Thus, GHK-Cu exhibits
antioxidant function in wounds by inhibiting ferritin iron
release in damaged tissues, preventing inﬂammation and
microbial infections [37]. GHK-Cu produced a 75% reduc-
tion of gastric mucosa homogenates of lipid peroxidation
in the range 10–100mM suggesting that copper-peptide
complexesareabletoeﬀectivelyneutralizedamagingoxygen-
derived free radicals [38].
GHK (in this experiment the peptide alone, not its
copper complex, was used) has been proven to quench
alpha,beta-4-hydroxy-trans-2-nonenal—a toxic product of
fatty acids’ lipid peroxidation that play important role in
the pathogenesis of several age-related conditions including
Alzheimer’s disease, neuropathy, and retinopathy [39]. GHK
peptide was also able to quench acrolein—another toxic
product of lipid peroxidation involved in the development
of many age-related degenerative disorders. The authors
proposed that GHK may be used for prevention of some age-
related pathologies, including Alzheimer’s disease [40].
Inﬂammation and oxidative damage due to the over-
production of proinﬂammatory cytokines play an important
role in the development of AD and other neurodegenerative
conditions [41]. In 2001 McCormack et al. established
that GHK-Cu decreased proinﬂammatory cytokine TGF-
beta in human ﬁbroblast culture [42]. In 2003 Canapp et al.
demonstrated that GHK-Cu improved healing of ischemic
wounds and suppresses inﬂammation by lowering the level
ofacute-phaseinﬂammatorycytokinessuchasTGF-betaand
TNF-alpha [43].
5.GHKStimulatesBloodVesselGrowth
Vascular factors play an important role in the development
of many neurodegenerative diseases of aging. Since the brain
is a highly metabolically active organ and requires constant
supply of oxygen and nutrients, a well-developed, adequate
vascular network is essential for its health [44].
From wound healing studies, it is known that GHK-Cu
helps reestablish blood ﬂow into damaged tissues through
a mixture of three actions: angiogenesis (new blood-vessel
formation), anticoagulation, and vasodilation. GHK-Cu
increases the expression of basic ﬁbroblast growth factor
and vascular endothelial growth factor, both of which aid
blood vessel formation [45]. In addition GHK-Cu’s ability4 Oxidative Medicine and Cellular Longevity
to stimulate synthesis of collagen and elastin is useful in
restoring integrity of blood vessel walls.
Sage et al. observed that endothelial cells at the site of
an injury produce a protein called SPARC that contains
GHK sequence. SPARC protein turned out to be abundant
in all tissues that undergo rapid remodeling such as skin
or embryonic tissues. When the tissue is damaged, tissue
proteases break down SPARC, releasing an array of GHK and
GHK-containing copper-binding peptides, which stimulate
cell proliferation and new vessels growth. When blood ﬂow
is suﬃciently restored, SPARC inhibits cell proliferation and
growth, controlling new vessels progression [46].
6. GHKIncreasesNeurotrophins
Among compounds that have a protective eﬀect and can
reduce oxidative damage are some neurotrophic factors such
as brain-derived neurotrophic factor (BDNF) [47]. There
is evidence that GHK increases production of neurotrophic
factors. Both Sensenbrenner et al. and Lindner et al. found
that GHK stimulates the outgrowth of cultured nerves [48,
49]. Ahmed et al. established that nerve stubs placed in a
collagen tube impregnated with GHK (used without copper)
had an increased production of nerve growth factor and
the neurotrophins NT-3 and NT-4 increased migration of
cells into collagen tube and sped up the regeneration of
nerveﬁbers.Inaddition,GHKalsoincreasedaxoncountand
proliferation of the Schwann cells compared to the control
group [50].
7.GHKasa GeneRegulator
Epigenetic modiﬁcation of gene expression is currently
considered a link between the environment, aging, and
neurodegeneration. It has been shown that some dietary
and environmental factors, such as certain toxins, may result
in abnormal DNA methylation and histone modiﬁcation,
altering gene activity. Recent studies revealed that some
well-known antioxidant and anti-inﬂammatory substances
such as plant ﬂavonoids may counteract these deleterious
changes by modulating activity of certain genes, reducing
glial inﬂammation and inhibiting production of neurotoxins
[51, 52].
First evidence that GHK-Cu may regulate an activity of
certain genes came from wound healing and skin remodeling
studies. By 1983, Pickart had established that GHK-Cu accel-
erates wound healing and contraction, improves the take
of transplanted skin, and also possesses anti-inﬂammatory
actions [53, 54].
Subsequent studies directed by Maquart et al. (France)
demonstrated that GHK-Cu at a very low, nontoxic con-
centration (1–10 nanomolar) stimulated both the synthesis
and breakdown of collagen and glycosaminoglycans [55, 56].
It modulated an expression of both metalloproteinases and
their inhibitors (TIMP-1 and TIMP-2), improving wound
healing and facilitating skin remodeling processes [57]. In
2000 the same group demonstrated that GHK-Cu increased
mRNA for collagen, dermatan sulfate, chondroitin sulfate,
and a small proteoglycan decorin [58].
In 2009, a group of researchers from the Seoul National
University (Republic of Korea) demonstrated that GHK-Cu
in concentrations of 0.1–10 microM increases expression
of integrins and p63. Since these molecules are considered
proliferative markers of epidermal stem cells, the authors
concluded that GHK-Cu helps to maintain an active prolif-
erative state of epidermal stem cells [59].
Iorio et al. used a repository of transcriptional responses
to compounds, the Connectivity Map (cMap) [60], and
MANTRA software (http://mantra.tigem.it/) to explore net-
works of compounds producing similar transcriptional
responses. GHK, as one of the compounds studied, increased
mRNA production in 268 genes while suppressing 167 [61].
Also, Hong et al. used genome-wide proﬁling to identify
genetic biomarkers (genetic signature) for metastasis-prone
colorectal cancer as well as their perturbagens—substances
that modulated their expression. GHK suppressed RNA pro-
duction in 70% of 54 human genes overexpressed in patients
with an aggressive metastatic form of colon cancer and was
active at a low nontoxic 1 micromolar concentration [62].
8.The ConnectivityMap and
the GHK-Affected Genes
Our own studies using the Broad Institute’s Connectivity
Map (cMap) showed that GHK activates numerous genes
involved in nervous system physiology, development, and
maintenance. The Connectivity Map holds three GHK gene
expression proﬁles created using the GeneChip HT Human
Genome U133A Array. Two of the proﬁles emerged from
the treatment of the PC3 cell line; the other proﬁle came
from the cell line MCF7. All cell lines were treated with GHK
at 1 micromolar. By selecting all three gly-his-lys instances
we determined which genes are aﬀected. Most interesting
are the genes that are remarkably up- and downregulated.
Using the cMap one can enter amplitude thresholds for
both up- and downregulated genes in order to ﬁnd the
genes whose expression are signiﬁcantly altered. With an up
gene amplitude threshold of 0.40 (equivalent to a 1.5-fold
induction) and a down gene amplitude threshold of −0.40
(equivalent to a 1.5-fold repression), we discover that 76
genes lay above the up threshold and 6 lay below the down
threshold.
In the cMap genes are represented by probe set IDs
in the tag lists, which identify the up- and downregu-
lated genes. Running the probe set IDs in the tag lists
through the “Batch query” in the NetAﬀx Analysis Center
(http://www.aﬀymetrix.com/), annotations for each probe
set are retrieved. Reviewing the annotations we observe
that 5 genes associated with nerves are stimulated (mRNA
expression is increased) by GHK while none are suppressed
(mRNA expression is decreased). These 5 genes are listed in
Table 1 along with their corresponding average fold change.
9.GHKM a yR ev e rseGe neS ile ncing
Epigenetic silencing of certain genes is currently con-
sidered the main reason for age-associated increase inOxidative Medicine and Cellular Longevity 5
Table 1
Probe set ID Gene symbol Gene products and functions (from GENE database;
http://www.ncbi.nlm.nih.gov/gene) Fold change∗
214484 s at SIGMAR1
Sigma nonopioid intracellular receptor 1, plays an important role in the
cellular functions of various tissues associated with the endocrine,
immune, and nervous systems. Mutations are implicated in early-onset
dementia and neurodegeneration.
2.46
205231 s at EPM2A
Laforin, a dual-speciﬁcity phosphatase associates with polyribosomes.
This gene is defective in a neurodegenerative disorder associated with
epileptic seizures (Lafora disease). Possibly a repair enzyme.
2.32
204860 s at NAIP Apoptosis inhibitory protein; functions include suppression of neuronal
apoptosis 2.13
208229 at FGFR2 Fibroblast growth factor receptor 2, inﬂuences mitogenesis and
diﬀerentiation, important in embryonic brain development. 1.9
209897 s at SLIT2
Slit homolog 2, neuronal repellent factor, nervous system development;
downregulation of this gene by neuronal diﬀerentiation factor promotes
tumor growth in neuroblastomas [63].
1.67
∗ThisrepresentstheaveragefoldchangeofgeneexpressionofthethreeGHKinstancesproﬁledinthecMap.Furthermore,itshouldbenotedthatallinstances
were performed using doses of GHK at 1 micromolar. Peak cellular responses to GHK have been recorded at 1 nanomolar; higher doses can reduce the cellular
response [56].
tumorogenesis, oxidative stress, and inﬂammation. It is
commonly accepted that human health is at its best until
approximately the age of 20–25. It then begins to decline in
later years. Recent genetic studies demonstrated accumula-
tion of altered gene products in various tissues starting from
the age of 20–25 [64]. In later decades of life, the genes
produce less regenerative proteins but more inﬂammatory
and oncogenic genes. The key enzymes implicated in gene
silencing are the family of histone deacetylase proteins
(HDACs). Inhibitors of selected HDACs possess neuropro-
tective and neuroregenerative properties in animal models
of brain diseases and have been suggested as promising
therapeutic drugs [65]. Results from the Broad Institute’s
Connectivity Map and ChemBank found that GHK is a
strong inhibitor of several HDACs. Although the data was
collected for GHK without copper, we cannot exclude the
possibility that the actual gene regulator was the GHK
copper complex formed in the culture media, since, as it
was mentioned above, GHK can easily obtain copper from
otherbiological moleculessuchasalbumin. Itis alsopossible
that GHK and GHK-Cu have complimentary eﬀects on gene
activity. At present, it is not always possible to track gene
eﬀectstoitsproteinproduct;however,wemayconcludefrom
allexperimentaldataonGHK-Cueﬀectsthatthereversingof
gene silencing by GHK has protective and health-promoting
beneﬁts.
10. Therapeutic Administration of GHK-Cu
It is possible that administration of GHK-Cu could be used
as a preventive and regenerative therapy for senescent or
damaged brain tissue. Using GHK-Cu has an advantage over
using just GHK, since it alleviates copper deﬁciency without
the risk of oxidative damage. Even though it is yet not clear
whether or not the GHK-Cu peptide can pass the blood-
brain barrier, there is a high possibility that it will do so,
since GHK-Cu has a very high uptake into human skin,
easily passing through the lipids of the epidermal barrier
[66, 67]. The peptide could be administered intravenously
or orally when encapsulated into liposomes. Strong systemic
wound healing was induced in pigs at about 1.1mg GHK-
Cu per kilogram body weight which would correspond to
about75mgsinhumans.Thisisabout300-foldbelowGHK-
Cu’s toxic action (lowering of blood pressure). Much lower
dosages may also be eﬀective since GHK-Cu’s actions on cells
generally occur at a 1 nanomolar concentration [68].
11. Conclusion
The multifaceted nature of age-associated cognitive decline
calls for complex approaches that address all key factors
involved in the development of neurodegenerative disor-
ders such as oxidative stress, neuroinﬂammation, disrupted
bioavailability of copper, impaired circulation, and altered
gene expression.
The human tripeptide GHK has a long history of safe
use in wound healing and skin care; it is naturally occurring,
nontoxic, and is active at a very low nanomolar concentra-
tion. It readily forms complexes with copper, regulating its
metabolism and improving its bioavailability. It possesses
antioxidant, anti-inﬂammatory, and regenerative properties,
improves circulation, supports stem cell functions, and
promotes nerve outgrown and synthesis of neurotrophic
factors. Recent studies demonstrated its ability to regulate a
large number of human genes. At 1 micromolar it was able
to suppress 70% of genes overexpressed in metastatic colon
cancer. It upregulates p63 and integrins in epidermal stem
cells, increases collagen, glycosaminoglycans, and decorin
expression. Our studies with the Broad Institute’s Connec-
tivity Map revealed its ability to regulate a large number of
human genes including those that are involved in nervous
system physiology, development, and maintenance.
Even though it is not always possible to distinguish
between activity of GHK peptide and its copper complex6 Oxidative Medicine and Cellular Longevity
GHK-Cu,westronglybelievethatforthefuturetherapeutical
applications GHK-Cu should be used. Numerous studies
demonstrating pleiotropic health promoting and antiage
activity of the GHK-Cu peptide together with recent studies
revealing gene regulating activity of GHK suggest that this
compound may belong to a class of epigenetic modi-
ﬁers capable of exhibiting broad protective and restorative
actions, reducing harmful epigenetic changes caused by
environmental perturbagens. The GHK-Cu peptide should
be considered a promising neuroprotective agent capable
of preventing the development of common age-associated
neurodegenerative disorders.
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